News
Media
Conferences
CME/CE
Partners
Publications
Resources
Subscribe

Opinion|Videos|September 30, 2024

Importance of Diverse Mechanisms of Action to Effectively Treat NMOSD

Author(s)Jacqueline Nicholas, MD, MPH

Jacqueline Nicholas, MD MPH discusses the importance of targeting NMOSD through different mechanisms of action and highlight key points for communicating with neurologists about the role of the complement system in the disease.

Episodes in this series

EP. 1 Relapses and Disability Accumulation in NMOSD

EP. 1 Relapses and Disability Accumulation in NMOSD

EP. 2 Treatments With Higher Efficacy and Relapses in NMOSD

EP. 2 Treatments With Higher Efficacy and Relapses in NMOSD

EP. 3 Ravulizumab Long-Term Data and Management of NMOSD

EP. 3 Ravulizumab Long-Term Data and Management of NMOSD

EP. 4 The Evolving Understanding of NMOSD Pathophysiology and the Role of Complement System

EP. 4 The Evolving Understanding of NMOSD Pathophysiology and the Role of Complement System

EP. 5 Treatment Options to Manage and Prevent Relapses in NMOSD

EP. 5 Treatment Options to Manage and Prevent Relapses in NMOSD

EP. 6 Importance of Diverse Mechanisms of Action to Effectively Treat NMOSD

EP. 6 Importance of Diverse Mechanisms of Action to Effectively Treat NMOSD

EP. 7 Complement Inhibitors in NMOSD

EP. 7 Complement Inhibitors in NMOSD

EP. 8 Meningococcal Infection and NMOSD

EP. 8 Meningococcal Infection and NMOSD

EP. 9 Long-term NMOSD Data

EP. 9 Long-term NMOSD Data

EP. 10 Use of Long-term NMOSD Data in Clinical Practice

EP. 10 Use of Long-term NMOSD Data in Clinical Practice

Video content above is prompted by the following:

Why might it be important to target the disease through different mechanisms of actions?
What is important to communicate with neurologists about the role of the complement system in NMOSD?

Newsletter

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Latest CME

2026 Carolina Neuromuscular Disease Summit

In-Person + Virtual Event

2026 Carolina Neuromuscular Disease Summit

September 19-20, 2026

Increasing Awareness of Therapeutic Options for Thymidine Kinase 2 Deficiency (TK2d)

In-Person Event

Increasing Awareness of Therapeutic Options for Thymidine Kinase 2 Deficiency (TK2d)

October 16, 2026

Primary Care Education in Nashville

In-Person + Virtual Event

Primary Care Education in Nashville

October 20-21, 2026

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Zarazuela Zolkipli-Cunningham, MBChB, MRCP; Mary Kay Koenig, MD; Perry Shieh, MD, PhD, FAAN, FANA

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Basil T. Darras, MD

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Karissa Gable, MD

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Anne M. Connolly, MD, FAAN; Amy Moore, PhD

Expert Illustrations & Commentaries™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia Gravis

Expert Illustrations & Commentaries™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia Gravis

James F. Howard Jr, MD, FAAN; Katherine Ruzhansky, MD, MS

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

Vinay K. Puduvalli, MD; Manmeet Ahluwalia, MD, MBA, FASCO; Girish Dhall, MD

From Clue to Care: Rapid Recognition and Coordinated Management of Paraneoplastic LEMS in SCLC

From Clue to Care: Rapid Recognition and Coordinated Management of Paraneoplastic LEMS in SCLC

Millie Das, MD; Wade Iams, MD, MSCI; Ruham Nasany, MD

Collaborating Across the Continuum™: Integrating Novel Therapies Into Multidisciplinary Treatment Plans for Generalized Myasthenia Gravis

Collaborating Across the Continuum™: Integrating Novel Therapies Into Multidisciplinary Treatment Plans for Generalized Myasthenia Gravis

Abigail Schwaede, MD; Alexis Lizarraga, MD, MS

Community Collab: The Evolving Role of FcRN Inhibitors in the Management of Generalized Myasthenia Gravis (gMG)

Community Collab: The Evolving Role of FcRN Inhibitors in the Management of Generalized Myasthenia Gravis (gMG)

James F. Howard Jr, MD, FAAN; Tuan Vu, MD

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

Charu Aggarwal, MD, MPH, FASCO; Erminia Massarelli, MD, PhD, MS; Ruham Nasany, MD

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

FDA Priority Review Puts Satralizumab on Track as First MOGAD Drug

NeuroVoices: Jacqueline Becker, PhD, on Brain Fog, Alzheimer Risk, and Treatment Advances in Long COVID

Gene Therapy ETX101 Shows Sustained Seizure Reductions, Neurodevelopmental Gains in Updated POLARIS Data

AAN, AHS Issue Updated Guideline on Pharmacologic Migraine Prevention in Adults: FAQs

Investigational Zorevunersen Linked to Adaptive Gains in Dravet Syndrome